Want a chance to learn from and hobnob with the top leaders in the region’s biotech industry? BioNJ offers a chance to do just that at its inaugural CEO Summit on Friday, October 4, from 7 a.m. to 5 p.m. at the Bridgewater Marriott. Register at bionj.org. $550 members, $650 nonmembers.
The roster of speakers includes top executives from New Jersey and beyond, as well as investors, academics, and other members of the life sciences community. Among the speakers:
Robert J. Hugin, CEO of Celgene Corporation. Hugin has been with Celgene since 1999. The company is focused on discovering, developing and bringing to market drugs treating cancer and immune-inflammatory disease. Hugin, a Princeton graduate with an MBA from the University of Virginia, is also chairman of the Pharmaceutical Research and Manufacturers of America.
Andre Wyss, president of Novartis Corporation North America, and Novartis Pharmaceuticals. Wyss assumed this role in 2010 and has been with Novartis since 1984 when he was a chemistry apprentice for Sandoz in Basel. He has a degree in economics from the School of Economics and Business Administration in Zurich.
John F. Crowley, CEO of Amicus Therapeutics, a title he has held since 2005. Crowley was previously head of Orexigen Therapeutcs and before that Genzyme Therapeutics. He also held management positions at Bristol-Myers Squibb. Crowley is a graduate of Georgetown University’s School of Foreign Service, and has a law degree from Notre Dame and an MBA from Harvard Business School.
The summit will include presentations from Will Lewis, CEO of Insmed; David Pearson, president of Thrombogenics; and Spiro Rombotis, CEO of Cyclacel Pharmaceuticals.
A panel called “In the Trenches with Tranches: Financing Strategies for Growth will include Lorenzo Pellegrini, partner at Care Capital; Stuart Peltz, CEO of PTC Therapeutics; Chris Tyrrell, CEO of OfferBoard; Michael Wells, managing director of Princeton Biopharma Partners, and James Marino, partner at Dechert.
Another panel, “Inside Outsourcing,” will feature John Barry, Merck’s global head of vendor management for development; Sally Macaluso, VP at Janssen R&D procurement; Ralph Marcello, principal of Deloitte; Raymond Hill, president of inVentiv Health Clinical; and John Watson, an executive at Covance. It will be moderated by John Fraher, president of Aptalis Pharma.
The “How Wide is the Crack in the IPO Window?” panel will be moderated by Hector G. Calzada Jr., managing director of Deloitte Corporate Finance, and will feature Kenneth I. Moch, CEO of Chimerix, Christian S. Schade, CFO of Omthera Pharmaceuticals, and Panna Sharma, CEO of Cancer Genetics.
“Billion Dollar Babies” will be moderated by Julie Kampf, CEO of JBK Associates, and will include Anthony Marucci, founder and CEO of Celldex Therapeutics, Francois Nader, CEO of NPS Pharmaceuticals, and Glenn Sblendorio, president of the Medicines Company.
